Evidence / Zwaan et al. · 2026
Mushroom powder and influenza vaccination responses
Selected research. Study type, product relevance and limitations are shown separately.
Editorial study summary
- Study type
- Randomized, double-blind, placebo-controlled human food intervention.
- Product relevance
- Indirect evidence from whole mushroom powder with ergothioneine measured in blood.
- Sample or population
- 85 men and women aged 60 or older.
- Studied dose
- 5 g/day of Agaricus bisporus powder or placebo. The abstract does not report the ergothioneine dose.
- Duration
- 8 weeks around vaccination.
- Finding
- Ergothioneine rose in the intervention group. IgM and IgG responses did not significantly differ between groups. The abstract also reports no differences in influenza-like illness or quality of life.
- Limitations
- The study tested whole mushroom powder. Blood ergothioneine was an exposure marker, and the immune outcomes did not establish a vaccination benefit.
- Study quality
- Randomized parallel-group design with placebo. Editorial review was limited to the abstract. No formal risk-of-bias rating was assigned.
- Funding and disclosures
- Funding and conflicts were not verified from the abstract.
The studies discussed here examine ingredients or other formulations. They do not establish results for this DR.MORGAN finished product.